{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T18:45:55Z","timestamp":1782585955459,"version":"3.54.5"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Modified Vaccinia Ankara\u2013Bavarian Nordic vaccination (MVA-BN) prevents mpox, whether offered subcutaneously or intradermally. Intradermal administration has been implemented as a dose-sparing strategy, but evidence on durability of protection and long-term clinical impact is limited. We evaluated mpox severity over time in a limited number of mpox cases following primary intradermal MVA-BN vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective case series of laboratory-confirmed mpox diagnosed between January 2024 and October 2025 at a major HIV and sexual health center in Stockholm, Sweden. Demographic and clinical data, vaccination history, and treatment outcomes were extracted from medical records. Disease severity was assessed using the validated Mpox Severity Score System.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy-nine patients were included (median age, 40 years); 32 unvaccinated and 47 had prior vaccination with smallpox vaccine (n = 6), smallpox plus MVA-BN (n = 11), or MVA-BN only (n = 30). All MVA-BN doses were administered intradermally. Breakthrough infections occurred a median of 22 months after MVA-BN vaccination. Vaccinated individuals had significantly milder disease, with lower median severity score (5.0 vs 8.0; P &amp;lt; .0001), fewer lesions, more limited distribution, and less mucosal involvement. No MVA-BN-vaccinated patient developed complications with bacterial superinfection (P = .002), and analgesic requirements were reduced (P = .004). Disease severity showed a modest inverse correlation with time since vaccination (r = \u22120.42, P = .01). Similar attenuation was observed in vaccinated individuals with well-controlled HIV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dose-sparing intradermal MVA-BN vaccination is associated with sustained reduction in mpox severity for up to 3 years. Continued vaccination of high-risk populations is supported, while prospective studies are needed to clarify long-term protection and optimize vaccination strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag337","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:23:51Z","timestamp":1780313031000},"source":"Crossref","is-referenced-by-count":0,"title":["Mpox Disease Severity Reduced in Intradermally MVA-BN Vaccinated Compared to Unvaccinated Patients in Sweden: A Retrospective 2024\u20132025 Observational Case-series"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0463-3764","authenticated-orcid":false,"given":"Catharina","family":"Missailidis","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases\/Venh\u00e4lsan, S\u00f6dersjukhuset , Stockholm ,","place":["Sweden"]},{"name":"Department of Clinical Science and Education, Karolinska Institutet S\u00f6dersjukhuset , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Mia","family":"Ekstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases\/Venh\u00e4lsan, S\u00f6dersjukhuset , Stockholm ,","place":["Sweden"]},{"name":"Department of Clinical Science and Education, Karolinska Institutet S\u00f6dersjukhuset , Stockholm ,","place":["Sweden"]},{"name":"Department of Global Public Health, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6242-3614","authenticated-orcid":false,"given":"Finn","family":"Fil\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases\/Venh\u00e4lsan, S\u00f6dersjukhuset , Stockholm ,","place":["Sweden"]},{"name":"Department of Clinical Science and Education, Karolinska Institutet S\u00f6dersjukhuset , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9736-7727","authenticated-orcid":false,"given":"Andreas","family":"Jacks","sequence":"additional","affiliation":[{"name":"Department of Communicable Disease Prevention and Control Stockholm Region , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5713-0071","authenticated-orcid":false,"given":"Katarina","family":"Widgren","sequence":"additional","affiliation":[{"name":"Department of Communicable Disease Prevention and Control Stockholm Region , Stockholm ,","place":["Sweden"]},{"name":"Department of Medicine, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Gisslen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg , Gothenburg ,","place":["Sweden"]},{"name":"Department of Infectious Diseases, Sahlgrenska University Hospital , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klara","family":"Sond\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"Department of Microbiology, Public Health Agency of Sweden , Solna ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Johansen","sequence":"additional","affiliation":[{"name":"Department of Global Public Health, Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"Department of Microbiology, Public Health Agency of Sweden , Solna ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"2026062714215061300_ofag337-B1","author":"WHO"},{"key":"2026062714215061300_ofag337-B2","author":"WHO"},{"key":"2026062714215061300_ofag337-B3","author":"EMA"},{"key":"2026062714215061300_ofag337-B4","author":"Folh\u00e4lsomyndigheten"},{"key":"2026062714215061300_ofag337-B5","doi-asserted-by":"crossref","first-page":"126409","DOI":"10.1016\/j.vaccine.2024.126409","article-title":"MVA-BN vaccine effectiveness: a systematic review of real-world evidence in outbreak settings","volume":"42","author":"Mason","year":"2024","journal-title":"Vaccine"},{"key":"2026062714215061300_ofag337-B6","doi-asserted-by":"crossref","first-page":"126053","DOI":"10.1016\/j.vaccine.2024.06.021","article-title":"Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: a systematic review and meta-analysis","volume":"42","author":"Pischel","year":"2024","journal-title":"Vaccine"},{"key":"2026062714215061300_ofag337-B7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1473-3099(23)00492-9","article-title":"Mpox in people with past infection or a complete vaccination course: a global case series","volume":"24","author":"Hazra","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2026062714215061300_ofag337-B8","doi-asserted-by":"crossref","first-page":"553","DOI":"10.15585\/mmwr.mm7220a3","article-title":"Estimated effectiveness of JYNNEOS vaccine in preventing mpox: a multijurisdictional case-control study - United States, August 19, 2022-March 31, 2023","volume":"72","author":"Dalton","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026062714215061300_ofag337-B9","doi-asserted-by":"crossref","first-page":"S229","DOI":"10.1093\/infdis\/jiad492","article-title":"Development and pilot of an mpox severity scoring system","volume":"229","author":"Zucker","year":"2024","journal-title":"J Infect Dis"},{"key":"2026062714215061300_ofag337-B10","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.cmi.2024.03.038","article-title":"History of smallpox vaccination and marked clinical expression of mpox among cases notified in France from May to July 2022","volume":"30","author":"Krug","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2026062714215061300_ofag337-B11","doi-asserted-by":"crossref","first-page":"105289","DOI":"10.1016\/j.ebiom.2024.105289","article-title":"Clinical and laboratory predictors of mpox severity and duration: an Italian multicentre cohort study (mpox-Icona)","volume":"107","author":"Mazzotta","year":"2024","journal-title":"eBioMedicine"},{"key":"2026062714215061300_ofag337-B12","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.3390\/microorganisms11112701","article-title":"Mpox: clinical outcomes and impact of vaccination in people with and without HIV: a population-wide study","volume":"11","author":"Mart\u00edn-Iguacel","year":"2023","journal-title":"Microorganisms"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag337\/68467401\/ofag337.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/6\/ofag337\/68467401\/ofag337.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/6\/ofag337\/68467401\/ofag337.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T18:22:01Z","timestamp":1782584521000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag337\/8701354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag337","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,6]]},"article-number":"ofag337"}}